



Systematic Review

Efficacy and safety of stenting and additional oncological treatment versus stenting alone in unresectable esophageal cancer: A meta-analysis and systematic review



Benedek Tinusz^{a,b}, Alexandra Soós^c, Péter Hegyi^c, Patrícia Sarlós^d, László Szapáry^c, Adrienn Erős^c, Donáta Feczák^c, Zsolt Szakács^c, Katalin Márta^c, Viktória Venglovecz^e, Bálint Eröss^{c,*}

^aInstitute for Translational Medicine, Medical School, Szentágotthai Research Centre; ^b1st Department of Internal Medicine, Medical School; ^cInstitute for Translational Medicine, Medical School, Szentágotthai Research Centre, University of Pécs, Hungary; ^dDepartment of Gastroenterology, 1st Department of Medicine, Medical School, University of Pécs, Hungary; ^eDepartment of Pharmacology and Pharmacotherapy, University of Szeged, Hungary

ARTICLE INFO

Article history:

Received 24 July 2019

Received in revised form 30 April 2020

Accepted 11 May 2020

Available online 15 May 2020

Keywords:

Esophageal cancer
Malignant stricture
Esophageal stent
Irradiation stent
Palliation

ABSTRACT

Aim: To compare the efficacy and safety of stent insertion alone to stent insertion combined with any active oncological treatment in the palliative care of esophageal cancer.

Methods: A meta-analysis and systematic review were performed according to the PRISMA Statement. Comparative studies with patients receiving stent insertion alone (control group) were compared to patients receiving oncological therapy in addition to stent placement (intervention group). For mean dysphagia grade before stenting, weighted mean differences (WMD), for the complications of stenting, risk ratios (RR) were calculated, both were interpreted with 95% confidence intervals (CI). Whenever possible, subgroup analyses were performed for studies with irradiation stents as intervention. Survival, late dysphagia, esophageal perforation and medical costs were analyzed via systematic review. The protocol of the study was registered prior on PROSPERO.

Results: 17 studies with 1177 esophageal cancer patients were included in the final analysis, with 629 and 548 in the control and intervention groups, respectively. We found no significant difference in any complications of stenting between the two groups. 13 studies reported mean or median survival, and 8 found that combined therapy resulted in a significantly longer life expectancy. In the other 5 studies, there was no difference in survival between the two groups. Furthermore, additional treatment may be more effective in the long-term relief of dysphagia than stenting alone.

Conclusions: Irradiation stents may prolong survival, and stenting combined with oncological treatment does not increase the risk of complications as compared to stenting alone. However, further studies are warranted.

Core tip: Esophageal cancer is the eighth most common type of malignancy worldwide, and its prognosis is very poor. This suggests that palliative treatment modalities are paramount in its treatment. Self-expanding metal stents play an important role in the management of dysphagia caused by the tumor. However, it is unclear whether any additional oncological therapy should be administered to patients besides stenting. In this meta-analysis and systematic review, we evaluated the safety and efficacy of additional oncological therapies alongside stenting versus stenting alone in case of unresectable esophageal cancer.

© 2020 Published by Elsevier B.V. Radiotherapy and Oncology 147 (2020) 169–177

Esophageal cancer is the eighth most common cancer worldwide with an estimated annual incidence and mortality above 572,000 and 508,000, respectively [1]. This makes it the sixth leading cause for cancer-related mortality [2]. Its five-year survival rate is estimated to be as low as 14% [3] and patients with metastatic

disease have a median survival of less than one year if treated with chemotherapy [4].

Low survival rates are also explained by the fact that the majority of tumors are unresectable at the time of diagnosis [3]. In most cases the diagnosis is made after the onset of dysphagia, which indicates at least locally advanced cancer [5]. The most common symptom is dysphagia in 74% of patients at the time of diagnosis [6]. Absence of early symptoms and the lack of precancerous states make screening procedures difficult to organize effectively [3],

* Corresponding author at: Institute for Translational Medicine, Medical School, University of Pécs, Szigei út 12, Pécs 7624, Hungary.

E-mail address: eross.balint@pte.hu (B. Eröss).

with the exception of Barrett's esophagus, where surveillance is recommended [7].

Such high mortality rates underline the importance of palliative treatment options. Endoscopic stenting with metal stents plays an important role in the management of malignant dysphagia to achieve immediate dysphagia relief and quality of life improvement [8].

Currently, there are no clear guidelines on whether additional oncological treatment is required besides stenting in the palliative care of esophageal cancers [9]. Stenting may be combined with various types on oncological treatment, including photodynamic therapy, brachytherapy (irradiation stents), radiotherapy, chemotherapy, or chemo-radiotherapy. At present, the decision lies in the hands of individual clinicians, and is usually based on patient characteristics, such as performance status, presence of metastases, age and expected survival time [9].

Our study aims to quantitatively and qualitatively analyze the potential benefits, drawbacks and safety measures of oncological treatment administered in addition to palliative stenting for incurable esophageal cancer.

Methods

We conducted a meta-analysis and systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement [10]. Our work was performed in accordance with the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [11]. The protocol was registered in PROSPERO under registration number CRD42018093921 [12].

Search

Two independent authors (BT and LS) carried out a comprehensive search using six electronic databases (PubMed, EMBASE, the Cochrane Library, Web of Science, clinicaltrials.gov, and the WHO Global Health Library) with the purpose of gathering all relevant articles on the topic of palliative stent therapy in esophageal cancer patients from inception until 10 February 2020.

Our PICO items were as follows: we looked for studies on patients with incurable esophageal cancer (P) that compare two palliative treatment modalities: stent insertion alongside any additional active oncological therapy (I) or stent insertion alone (C). The primary outcomes were mean survival time after stent insertion and the relief of dysphagia. Secondary outcomes were the complications of stenting (such as hemorrhage, deaths due to hemorrhage, chest pain requiring opiate analgesics, fever, stent migration, restenosis or obstruction, tracheoesophageal fistula formation, aspirational pneumonia and esophageal perforation) and the cost of the medical treatment (O).

The query "(esophagus OR oesophagus) AND ((malignant* OR cancer* OR carcinoma) AND (stricture OR stenosis OR obstruction OR blockage OR dysphagia)) AND (stent OR onco* OR radio* OR chemo* OR beam OR best supportive OR palliat*)" was used in all six databases. For a draft of our search strategy, see [Supplementary 1](#).

The "human" filter was applied when searching in PubMed, EMBASE and the WHO Global Health Library. The "trials" and "completed" filters were used in case of the Cochrane Library and clinicaltrials.gov, respectively. We imposed no language restriction to our search.

Inclusion and exclusion criteria

We included both observational and interventional studies except for case studies, case reports, editorials, comments, letters and reviews. Conference abstracts were included if they contained

sufficient data for analysis. We included studies with either prospective or retrospective data collection, regardless of their primary objectives. In case of multiple publications on the same group of patients, the most recent record was chosen.

The inclusion criteria required patients to be over 18 years of age, with a diagnosis of incurable, late-stage esophageal cancer (of any histological subtype). An intervention and a control group both had to be present in the same study in order to provide comparability. The control group was defined as patients receiving any type of metallic stent implantation for palliative purposes, without the concurrent addition of other active treatment modality. The indication for stenting was malignant dysphagia. The intervention group consisted of those patients who received a metallic esophageal stent of any kind in combination with any type of active oncotherapy (radio-, chemo-, or photodynamic therapy) for palliative purposes. Insertion of irradiation stents was considered an intervention, as brachytherapy delivered by the stent is an additional active oncological treatment modality.

Screening and selection

Articles yielded by the initial search were imported into a reference management program (EndNote X7, Clarivate Analytics, Philadelphia, PA, USA). The same software was utilized for the removal of duplicates by searching for articles with overlapping publication year, authors or title.

After duplicate removal, two independent researchers (BT and LS) simultaneously screened all remaining articles against the pre-defined eligibility criteria first by title, abstract and then full text in order to find studies for inclusion. Reference lists of selected articles were searched to identify studies potentially missed by the electronic search. Any disagreements were resolved by arbitration by a third investigator (BE).

Data extraction

Two investigators separately extracted data from studies included and manually entered them on a Microsoft Excel 2016 sheet (Office 365, Microsoft, Redmond, WA, USA). Data were collected on first author, publication year, study type, geographical location, definition of control and intervention groups, demographical characteristics of patients included, and histological subtype of the tumors. Finally, data were collected on the aforementioned outcomes of interest. Differences in the data sheets were resolved by consensus.

Quality assessment and quality of evidence

We used a modified version of the Newcastle-Ottawa Scale (NOS) for the quality assessment of cohort studies included in our analysis [13]. [Supplementary 2](#) shows the NOS Quality Assessment Form for Cohort Studies modified to fit the study design of the articles included. The Cochrane Risk of Bias Tool was used to assess the quality of the randomized-controlled trials [14]. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to rate the quality of evidence as high (level A), moderate (level B), low (level C) or very low (level D) [15].

Data synthesis and analysis

In case of the survival time and the dysphagia grade weighted mean differences (WMD) were calculated with their 95% confidence intervals (CI). In other comparisons, risk ratios (RRs) with 95% CI were calculated from the raw data extracted. Subgroup analyses were also performed by treatment type. Pooled estimates

were calculated with random effects model by using DerSimonian–Laird method [16]. Results of the meta-analysis were displayed graphically using forest plots. Heterogeneity was tested by using the Cochrane’s Q and the I^2 statistics, where $I^2 = 100\% \times (Q - df) / Q$, and represents the magnitude of the heterogeneity (moderate: 30–60%, substantial: 50–90%, considerable: 75–100%) [11]. All meta-analytical calculations were performed by Stata v15.1 software (Stata Corp LLC, College Station, TX, USA).

Results

Our search yielded a total of 14,960 articles, 1226 in PubMed, 9505 in EMBASE, 355 in the Cochrane Library, 1503 in Web of Science, 2371 in the WHO Global Health Library, and 0 in clinicaltrials.gov. Four articles were identified by cross-referencing. After duplicate removal and three-step selection, a total of 40 articles were assessed for eligibility by their full text. Out of these studies, 23 were excluded for the following reasons: lack of intervention group (6 studies, [17–22]), lack of a control group (3 studies, [23–25]), insufficient outcome data (7 studies, [26–32]), use of non-metallic stents (2 studies, [33,34]), patients with curable cancer (2 studies, [35,36]) and curative intent (3 studies, [37–39]). For a summary of our search and selection, see Fig. 1: PRISMA flowchart of the study selection process.

Finally, 17 studies were deemed eligible for either qualitative or quantitative synthesis [40–56]. These included a total of 1177 subjects, out of which 629 and 548 patients received stent therapy alone (control group) or stent therapy supplemented by additional oncological treatment (intervention group), respectively. In case of 234 patients, brachytherapy with I^{125} -coated irradiation stents was the intervention method of choice, which provided basis for subgroup-analysis. Characteristics of studies included are shown in Table 1.

Tables 2 and 3 contain data collected on outcomes included in the meta-analysis, and Table 4 shows a summary of the results of the quantitative synthesis.




Fig. 1. PRISMA flowchart for the study selection process.

Complications of stenting. We found no significant association between additional oncological treatment and complications of the stenting procedure, such as chest pain requiring opiate analgesics (RR, 1.03; 95% CI, 0.84–1.26; I^2 0.0%; Supplementary 3), hemorrhage (RR, 1.32; 95% CI, 0.89–1.98; I^2 0.0%; Supplementary 4) and deaths due to hemorrhage (RR, 1.19; 95% CI, 0.67–2.11; I^2 0.0%; Supplementary 5). Neither increased risk of stent migration (RR, 0.96; 95% CI, 0.51–1.78; I^2 0.0%; Supplementary 6), nor stent restenosis or obstruction (RR, 0.62; 95% CI, 0.36–1.09; I^2 21.6%; Supplementary 7) were associated with additional treatment. Fistula formation and development of aspirational pneumonia and development of fever as complications of stenting also did not show association with additional active oncotherapy (RR, 1.62; 95% CI, 0.68–3.87; I^2 0.0%; RR, 0.76; 95% CI, 0.40–1.45; I^2 0.0%; RR, 1.24; 95% CI, 0.61–2.50; I^2 0.0%; Supplementary 8–10, respectively).

Subgroup-analyses of studies where irradiation stents were used [40,42,44,45,48,54,55] as intervention were performed whenever possible, showing no association with any of the complications examined (see Supplementary 3, 4, 6, 7, 8).

Dysphagia score before stenting and within 3 days of stenting. We found no significant difference between the two groups in dysphagia scores prior to and within 3 days of the stenting procedure (WMD, –0.03; 95% CI, –0.11–0.05; I^2 0.0%; WMD, 0.08; 95% CI, –0.01–0.17; I^2 0.0%; see Supplementary 11 and 12, respectively).

Table 5 demonstrates data extracted on outcomes analyzed in the systematic review section of our study.

Survival after stenting. 13 studies reported this outcome as mean or median survival time after stent insertion [40–46,48–51,54,55]. Out of the 13 articles, 12 compared the survival of patients in the two groups via log rank test [40–45,48–51,54,55]. These 12 articles included a total of 894 patients, out of which 473 and 421 belonged to the control and intervention group, respectively. The use of additional oncological treatment was associated with prolonged survival in 8 of these 12 studies [40,41,43,45,48,49,54,55] comparing a total of 542 patients, with 281 in the control group and 261 in the intervention group, respectively. The remaining 4 studies (352 total patients; 212 and 140 patients in the control and intervention group) found no significant difference between survival in the two groups [42,44,50,51]. No study showed significantly reduced survival time in patients that received stenting and additional oncological therapy as compared to stenting alone.

Regarding the sub-group of 7 articles (539 total patients, 254 and 285 patients in the control and intervention groups) where iodine-coated stents were used as intervention [40,42,44,45,48,54,55], 5 (345 total patients; 182 versus 163 patients in the control and intervention group) reported that that irradiation stents significantly prolong survival as compared to regular stents [40,45,48,54,55]. At the same time, 2 articles (194 patients, 72 in the control and 122 in the intervention group) found no significant difference between the two groups [42,44]. No articles suggested that irradiation stents are associated with reduced survival as compared to regular stents. Detailed results of this outcome in each study can be found in Table 6.

Late dysphagia. The studies contained insufficient data on dysphagia scores more than 3 days after the stenting procedure, therefore only quantitative synthesis was carried out in case of this outcome. 5 studies [40,42,48,49,57] of the included 17 contained data on the long-term improvement of dysphagia. Guo et al. found that dysphagia was equally well palliated in both groups up until the second month after treatment, where the intervention group had a significantly lower dysphagia score (exact dysphagia score values were not specified in the article, $p < 0.05$) [40]. Liu et al. concluded that there was no significant difference between dysphagia scores of patients in the control and intervention groups at 1 month after stenting (mean dysphagia score at 1 month 1.6 and 1.7 in the

Table 1
Characteristics of studies included.

Author (publication year)	Country	Design	Group definitions (C: Control; I: Intervention)	Patient Number (n)	Male (n)	Age (years, mean, SD)	Follow-up (months, mean)	Histology AC/SCC (n)
Bakheet (2019)	South Korea	Retrospective cohort	C: SEMS alone	41	38	67.7(11)		
Tian (2016)	China	Cohort	I: SEMS + chemotherapy C: SEMS alone	64 91	60 67	66.7(10.7) 66.3 (9.4)	4 (median)	0/90
Zhao (2016)	China	RCT	I: I ¹²⁵ -coated Irradiation stent C: SEMS alone	40 25	30	66.9 (8.6)	4 (median)	0/41 0/25
Kim (2015)	South Korea	Retrospective cohort	I: I125-coated Irradiation stent C: SEMS alone	18 45				0/18 7/10
Liu (2014)	China	Cohort	I: SEMS + multiple modalities of oncological treatment C: Conventional SEMS	44 32				3/9 5/27
Zhu (2014)	China	RCT	I: I125-coated Irradiation stent C: SEMS alone	31 75	16 53	59.6 71 (median)	2.7 4.1 (median)	6/25 14/61
Zhongmin (2012)	China	Cohort	I: I ¹²⁵ -coated irradiation stent C: Covered stent alone	73 30	61 18	71 (median) 68.8(6.9)	5.7 (median)	8/65 12/18
Xu (2011)	China	RCT	I: I ¹²⁵ -coated Irradiation stent C: SEMS alone	28 17	19	65(7.9)		8/20
Zhao (2011)	China	Cohort	C: SEMS alone I: I ¹²⁵ -coated Irradiation stent	15 25				
Burstow (2009)	Australia	Retrospective cohort	C: SEMS alone I: Adjuvant chemotherapy, radiotherapy, or both	67 23				
Guo (2008)	China	RCT	C: Conventional covered stent I: I ¹²⁵ -coated irradiation stent	27 26	20 19	69.54 (8.68) 72.19 (8.71)	3.3 7.2	6/20 5/22
Zhang (2005)	China	Cohort	C: Metal stent only I: Endoprosthesis and external radiotherapy	34 33	25 26	62.04 60.17		2/31 2/30
Fu (2004)	China	RCT	C: SEMS alone I: Stent + external radiotherapy and/or chemotherapy	27 26	16 23	64.2 (14) 59.4 (9.6)		2/23 2/24
Javed (2004)	India	RCT	C: SEMS alone I: Stent + external beam radiotherapy	37 42	27 29	58.1 (12.44) 58.6 (12.13)		6/31 7/35
Zhong (2003)	China	Cohort	C: SEMS alone I: SEMS + external radiotherapy and/or chemotherapy	18 16	13 12	64.6 61.5		0/18 0/16
Ludwig (1998)	Germany	Cohort	C: Nitinol stent or wallstent I: stent combined with radiochemotherapy	17 12	13 11	67 (median) 57 (median)		7/10 3/9
Raijman (1997)	USA	Retrospective cohort	C: Coated expandable wallstent alone I: Stent + chemo/radio/both	21 39	10 29	66.8 64.7	6.4 5.9	8/13 12/14

control and intervention group, respectively, $p = 0.91$). At 3 months, however, the difference between the two groups became significant (mean dysphagia scores 2.6 vs 2.1 in the control and intervention groups, respectively, $p = 0.03$) [42]. In case of the article by Zhu et al., dysphagia was significantly lower in the intervention group as compared to the control group starting from 1 month after the procedure to the end of the follow-up [48]. Javed et al. states that the mean dysphagia score was comparable between the two groups up until 3 months post-treatment. Thereafter, dysphagia scores at 5 and 7 months were significantly lower in the intervention group [49]. Zhong et al. found that stenting dramatically improved dysphagia of patients, however patients in the control group had an increasing tendency of dysphagia grades 9 months after stent implantation (mean dysphagia in the control and intervention groups at 9 months after stenting; $1.75(\pm 0.35)$ 4 and $1.58(\pm 38)$ respectively; statistical analysis not reported).

Perforation. 5 studies [42,45,47,49,53] on a total of 312 patients included data concerning esophageal perforation (or a lack thereof) as a complication of stenting. Perforation only occurred in two studies [42,53], with a combined rate of 6.1% (4/66) and 9.4% (6/64) in the control and intervention group, respectively. Out of the total 182 patients (83 in the control group and 99 in the intervention group) of the other 3 studies [45,47,49], no perforation was observed. None of the articles found a significant difference between the two groups ($p = 0.672$ in case Liu et al.).

Medical costs. Only one article out of 17 [44] assessed medical costs as an outcome. They reported that regular stent treatment received by the control group to be significantly cheaper than treatment with irradiation stent in the intervention group (7000 and 26,000 Chinese yuan, approximately 1000 and 3800 USD respectively, $p < 0.01$) [44].

Supplementary 16 and 17 represent the results of the quality assessment of the studies included.

Applying the GRADE approach to each of the outcomes assessed above resulted in a very low (D) level of evidence for every outcome.

Discussion

It is established knowledge that self-expanding metal stent insertion provides an acute relief of malignant dysphagia with an immediate success rate of 90–100% [57,58]. At the same time, recurring dysphagia within 4 to 10 weeks after stenting occurs in around 50% of patients [38,59]. On the other hand, radiotherapy exceeds at relieving long-term dysphagia [60], but the onset of its beneficial effects is slow, and may even worsen dysphagia early on due to radiation-induced swelling [49].

A randomized-controlled trial in 2005 demonstrated longer ongoing dysphagia relief with radiotherapy than stent alone [37].

Table 2

Data extracted on outcomes synthesized via meta-analysis, part 1.

Author (year of publication)	Group (C: control; I: intervention)	Patient Number (n)	Severe chest pain (n)	Hemorrhage (n)	Deaths due to hemorrhage (n)	Stent migration (n)	Restenosis/stent obstruction (n)
Bakheet (2019)	C	41				2	
	I	64				8	
Tian (2016)	C	91	16	6	6	5	4
	I	40	12	1	1	2	2
Zhao (2016)	C	25	3	0	0	0	3
	I	18	2	0	0	0	2
Kim (2015)	C	45					
	I	44					
Liu (2014)	C	32	9	7	3	4	
	I	31	8	11	4	3	
Zhu (2014)	C	75	15	5	5	0	
	I	73	17	5	6	0	
Zhongmin (2012)	C	30	24			2	2
	I	28	15			1	1
Xu (2011)	C	17	4	4			7
	I	15	3	4			3
Zhao (2011)	C	25	4	0		0	
	I	18	3	0		0	
Burstow (2009)	C	67					
	I	23					
Guo (2008)	C	27	7	7	7	3	6
	I	26	8	9	9	2	8
Zhang (2005)	C	34		3		3	7
	I	33		7		2	1
Fu (2004)	C	27	4	1			9
	I	26	7	2			1
Javed (2004)	C	37				0	9
	I	42				1	6
Zhong (2003)	C	18	1	2		1	
	I	16	0	3		0	
Ludwig (1998)	C	17					
	I	12					
Raijman (1997)	C	21	4	2			
	I	39	9	2			

Table 3

Data extracted on outcomes synthesized via meta-analysis, part 2.

Author (year of publication)	Group (C: control; I: intervention)	Patient Number (n)	Mean dysphagia grade before stenting ^a	Mean dysphagia grade within 3 days of stenting ^a	Fistula formation (n)	Aspirational pneumonia (n)
Bakheet (2019)	C	41	3.15	1.17		
	I	64	3.17	1.14		
Tian (2016)	C	91	3.27	0.20		
	I	40	3.28	0.38		
Zhao (2016)	C	25				
	I	18				
Kim (2015)	C	45				
	I	44				
Liu (2014)	C	32	3.03		1	3
	I	31	3.10		2	2
Zhu (2014)	C	75	3.40	1.30	5	14
	I	73	3.30	1.40	6	11
Zhongmin (2012)	C	30	3.40			
	I	28	3.43			
Xu (2011)	C	17				
	I	15				
Zhao (2011)	C	25				
	I	18				
Burstow (2009)	C	67				
	I	23				
Guo (2008)	C	27	3.12	1.04	0	2
	I	26	3.22	1.07	1	1
Zhang (2005)	C	34	2.15		1	
	I	33	2.18		3	
Fu (2004)	C	27				
	I	26				
Javed (2004)	C	37	3.22		0	
	I	42	3.10		0	
Zhong (2003)	C	18	3.11			
	I	16	3.06			
Ludwig (1998)	C	17				
	I	12				
Raijman (1997)	C	21	3.60	1.40		
	I	39	3.50	1.40		

^a Measured on a 4-grade scale.

Table 4
Results of the meta-analysis.

	N of studies	RR or WMD	(95% CI)	I ² (%)
Chest pain requiring opioids				
All studies ^a	12	1.03	(0.84–1.26)	0.0
Irradiation stent only	8	0.96	(0.84–1.26)	5.2
Other oncological treatment	4	1.03	(0.63–4.21)	0.0
Hemorrhage				
All studies ^a	11	1.32	(0.89–1.98)	0.0
Irradiation stent only	7	1.25	(0.79–1.97)	0.0
Other oncological treatment	4	1.62	(0.71–3.71)	0.0
Deaths due to hemorrhage				
Irradiation stent only ^c	5	1.19	(0.67–2.11)	0.0
Stent migration				
All studies ^a	11	0.96	(0.51–1.78)	0.0
Irradiation stent only	7	0.78	(0.35–1.71)	0.0
Other oncological treatment	4	1.34	(0.49–3.68)	0.0
Stent restenosis				
All studies ^a	8	0.62	(0.36–1.09)	21.6
Irradiation stent only	5	0.92	(0.51–1.66)	0.0
Other oncological treatment	3	0.29	(0.09–0.93)	39.7
Fistula formation				
All studies ^a	5	1.62	(0.68–3.87)	0.0
Irradiation stent only	3	1.47	(0.55–3.91)	0.0
Other oncological treatment	2	2.35	(0.34–16.10)	0.0
Aspirational pneumonia				
All studies ^a	3	0.76	(0.40–1.45)	0.0
Fever				
All studies ^a	3	1.24	(0.61–2.50)	0.0
Dysphagia grade before stenting				
All studies ^a	7	−0.03 ^b	(−0.11–0.05)	0.0
Dysphagia grade after stenting within 3 days				
All studies ^a	4	0.08 ^b	(−0.01–0.17)	0.0

OR: odds ratio; WMD: weighted mean difference.

^a All studies where the corresponding outcome was reported.

^b Weighted mean difference.

^c Only studies with irradiation stents contained this outcome.

The complementary effects of the immediate relief from the stent insertion and the long term effect of brachytherapy make the combination of palliative stenting and radiotherapy a rational decision. Several individual studies suggest that brachytherapy using irradiation stents is associated with prolonged survival, in addition to the effective treatment of dysphagia (both acutely and on the long-term) [56,61].

Our meta-analysis did not find a significant difference in any assessed complications of stenting between the two groups, which suggests that active oncological therapy combined with stenting is non-inferior to stenting alone in terms of its safety. Our analysis did not cover the potential differences in quality of life between the two groups; however we believe this to be an important parameter to monitor, which should be taken into consideration when designing future trials.

Limitations and explanation of heterogeneity

While conducting the meta-analysis, we came across several limitations that may potentially impair the strength of our findings.

Regarding differences in patient populations, the tumor stage of involved patients varied from study to study. The articles reported this characteristic inconsistently, by describing the mean tumor stage [44,48,50], the number of patients with metastatic cancer [40,42,49,50], or the ECOG performance scale of the patients [48].

Methodological differences between studies include that the modality of active oncological treatment was not the same in every article. Most studies utilized I¹²⁵-coated irradiation stents in the

intervention group [40,42,44,45,48,54,55]. In other cases, external radiotherapy, chemotherapy or both were applied in addition to stenting as intervention [41,43,46,47,49,50].

Statistical methods did not reveal the causes for heterogeneity among the included studies. The major confounding factors accounting for the heterogeneity are likely the differences between the populations (age, gender ratio, histological type of cancer) in the individual studies, the differences between the standard of palliative care. Chronological bias may be another important confounder as studies spread between 1997 and 2019.

Another methodological difference is the inconsistency of follow-up periods. Only 5 studies out of the analyzed 17 included data on the follow-up time of patients [40,42,44,47,48].

In case of two articles, patients were allowed to receive different treatment in addition to the treatment modalities of their assigned group. In Zhao et al., the use of alternative medicine and chemotherapy was allowed before, concurrently with, or after the assigned treatment [45]. In the study conducted by Guo et al., some patients received traditional Chinese medicine as well as their assigned treatment [40].

With regards to the outcomes assessed, we found slight differences in the definition of dysphagia between studies. Although every article that assessed dysphagia did so as a 0–4 scale, the definition of each value varied slightly.

Generalizability of the findings is questionable as the majority of studies are from China, some, from the same center, with squamous cell cancer as the predominant type of esophageal cancer. As environmental and genetic factors may be very different, the results above may not be reproducible in Western populations.

Table 5Data extracted on outcomes synthesized via systematic review ^ameasured on a 4-grade scale, ^bmeasure of effect not specified in the article.

Author (year of publication)	Group (C: control; I: intervention)	Patient Number (n)	Mean dysphagia grade after stenting at 1 month ^a	Mean dysphagia grade after stenting at 3 months ^a	Mean dysphagia grade after stenting at 5 months ^a	Fever (n)	Medical costs ^b (Chinese yuan)	Perforation (n)
Bakheet (2019)	C I	41 64						
Tian (2016)	C I	40 91					7000 26,000	
Zhao (2016)	C I	25 18						0 0
Kim (2015)	C I	45 44						
Liu (2014)	C I	32 31	1.60 1.70	2.60 2.10		4 6		3 2
Zhu (2014)	C I	75 73	1.76 1.74	2.56 1.85	2.65 1.87			
Zhongmin (2012)	C I	30 28						
Xu (2011)	C I	17 15				5 6		
Zhao (2011)	C I	25 18						
Burstow (2009)	C I	67 23						
Guo (2008)	C I	27 26	1.17 1.22			3 1		
Zhang (2005)	C I	34 33						1 4
Fu (2004)	C I	27 26						
Javed (2004)	C I	37 42		1.27 1.27	2.55 1.45			0 0
Zhong (2003)	C I	18 16		1.36 1.29				
Ludwig (1998)	C I	17 12						
Raijman (1997)	C I	21 39						0 0

Our meta-analysis found that stenting with additional active oncological therapy does not increase the risk for complications of stenting in case of patients diagnosed with unresectable esophageal cancer as compared to stenting alone. Furthermore, our systematic review strongly suggests that additional oncological therapy may prolong the survival of patients after stenting, and irradiation stents may be more effective in the relief of late dysphagia when compared to stenting alone.

However, due to the differences in study design, definition of outcomes and patient characteristics of the studies included, the quality of evidence remains very low. We believe that further large-scale, randomized-controlled trials are warranted to assess the effectiveness and safety of palliative treatment modalities in esophageal cancer.

Guarantor of the article

Bálint Eröss MD

Specific author contributions

Eröss B and Hegyi P conceptualized and designed the study in cooperation with Sarlós P; Tinusz B and Szakács Z constructed the search query and carried out the search process; Tinusz B, Szapáry L and Feczák D screened the articles for eligibility; Tinusz

B and Szapáry L performed the data extraction; Tinusz B and Eröss A conducted the quality assessment; Tinusz B and Eröss B wrote the article; Soós A carried out the statistical analysis; Márta K, Venglovecz V and Hegyi P provided valuable feedback after critically reviewing the first drafts of the manuscript. All authors reviewed and approved the final manuscript for publication.

PRISMA 2009 Checklist statement

The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised accordingly.

Statement of interests

1. Authors' declaration of personal interests:
The authors declare no competing interests.
2. Declaration of funding interests:

This work was supported by an Economic Development and Innovation Operative Programme Grant, GINOP 2.3.2-15-2016-00048 to PH; a Human Resources Development Operational Programme of the European Union and the Hungarian Government EFOP-3.6.2-16-2017-0006 to PH. Funding was also received from the ÚNKP-18-2-I New National Excellence Program within Hungary's Ministry of Human Capacities.

Table 6Detailed data on the survival outcome of our systematic review; ¹mean, ²median ³confidence interval, ⁴standard deviation, ⁵range.

Author (year of publication)	Design	Group definitions (C: Control; I: Intervention)	Patient number (n)	Survival time (months)	p value of the long-rank test
Bakheet (2019)	Retrospective cohort	C I	41 64	4.4 ¹ (3.23–5.57) ³ 5.2 ¹ (4.4–6.0) ³	0.592
Tian (2016)	Cohort	C I	40 91	4.2 ¹ (2.8) ⁴ 4.4 ¹ (2.4) ⁴	0.752
Zhao (2016)	RCT	C I	25 18	4.8 ¹ (3.9) ⁴ 9.8 ¹ (4.3) ⁴	<0.01
Kim (2015)	Retrospective cohort	C I	45 44	3.2 ¹ (3.0) ⁴ 5.6 ¹ (4.2) ⁴	<0.001
Liu (2014)	Cohort	C I	32 31	3.1 ¹ (2.6–3.6) ³ 3.7 ¹ (3.1–4.3) ³	0.064
Zhu (2014)	RCT	C I	75 73	4.9 ² (5.1–6.7) ⁵ 5.9 ² (4.1–5.7) ⁵	0.0046
Zhongmin (2012)	Cohort	C I	30 28	4.9 ² (1–12) ⁵ 11 ² (3–18) ⁵	<0.001
Zhao (2011)	Cohort	C I	25 18	4.8 ¹ (4.83–8.77) ³ 9.8 ¹ (9.43–12.83) ³	<0.01
Guo (2008)	RCT	C I	27 26	3.5 ¹ (2.72–4.16) ³ 8.3 ¹ (6.36–10.21) ³	<0.001
Fu (2004)	RCT	C I	27 26	8.17 ¹ (5.47–10.83) ³ 8.73 ¹ (6.97–11.5) ³	0.813
Javed (2004)	RCT	C I	37 42	42 62	0.009
Ludwig (1998)	Cohort	C I	17 12	4.6 ² (0.85–25.7) ⁵ 8.0 ² (0.3–10.57) ⁵	<0.05

ORCID numbers

Benedek Tinusz (0000-0001-6187-526); Alexandra Soós (0000-0001-9305-5251); Péter Hegyi (0000-0003-0399-7259); Patrícia Sarlós (0000-0002-5086-9455); László Szapáry (0000-0003-2056-0825); Adrienn Erős (0000-0001-6494-2708); Donáta Feczák (0000-0003-3946-2993); Zsolt Szakács (0000-0002-7035-941X); Katalin Márta (0000-0002-2213-4865); Viktória Venglovecz (0000-0002-2316-7247); Bálint Eröss (0000-0003-3658-842).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.radonc.2020.05.015>.

References

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394–424.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136:E359–86.
- Enzinger PC, Mayer RJ. Esophageal cancer. *N Engl J Med* 2003;349:2241–52.
- Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. *Semin Oncol* 1999;26(5 Suppl 15):12–20.
- Huang FL, Yu SJ. Esophageal cancer: risk factors, genetic association, and treatment. *Asian J Surg* 2018;41:210–5.
- Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. *J Am Coll Surg*, 2000;190(5):562–72; discussion 72–3.
- Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. *Am J Gastroenterol* 1998;93:1028–32.
- Hindy P, Hong J, Lam-Tsai Y, Gress F. A comprehensive review of esophageal stents. *Gastroenterol Hepatol* 2012;8:526–34.
- Steyerberg EW, Homs MY, Stokvis A, Essink-Bot ML, Siersema PD, Group SS. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. *Gastrointest Endosc*, 2005;62(3):333–40.
- Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*, 2009;151(4):264–9, W64.
- Chandler J, Hopewell S. Cochrane methods—twenty years experience in developing systematic review methods. *Syst Rev* 2013;2:76.
- Booth A, Clarke M, Dooley G, Gherzi D, Moher D, Petticrew M, et al. PROSPERO at one year: an evaluation of its utility. *Syst Rev* 2013;2:4.
- Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. *BMC Med Res Method* 2014;14:45.
- Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. *BMJ* 2015;350:h870.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177–88.
- Debevec M. Results of nonoperative treatment for esophageal cancer. *Radiol Oncol* 1994;28:129–33.
- Dimofte G, Crumpei F, Trifina L, Nicolescu S, Leanca D, Fu J-H, et al. Cost-effectiveness of endoscopically placed stents in the palliation of locally advanced esophageal carcinoma [Treatment of unresectable esophageal carcinoma by stenting with or without radiochemotherapy]. *Rom J Gastroenterol*. 2004;13:17–22.
- Antonello A, Realdon S, Diamantis G, Vecchiato M, Bocus P, Giacomini F, et al. Cervical esophageal stent placement: a 15-year experience. *Digest Liver Dis* 2014;46:S18.
- Bertschinger P, Hacki WH. Endoprostheses in palliative treatment of malignant esophageal stenosis. *Schweizerische Medizinische Wochenschrift* 1989;119:803–7.
- Homs MYV, Steyerberg EW, Eijkenboom WMH, Tilanus HW, Stalpers LJA, Bartelsman JFWM, et al. Palliative treatment of oesophageal cancer with dysphagia: More favourable outcome from single-dose internal brachytherapy than from the placement of a self-expanding stent; a multicentre randomised study. *Ned Tijdschr Geneesk* 2005;149:2800–6.
- Shenfine J, McNamee P, Steen N, Bond J, Griffin SM. A randomized controlled clinical trial of palliative therapies for patients with inoperable esophageal cancer. *Am J Gastroenterol* 2009;104:1674–85.
- Mao AW, Gao ZD, Xu JY, Yang RJ, Xiao XS, Jiang TH, et al. Treatment of malignant digestive tract obstruction by combined intraluminal stent installation and intra-arterial drug infusion. *World J Gastroenterol* 2001;7:587–92.
- Sehgal CM, Sharma RR, Kapoor R, Goel DR, Patel FD, Sharma SC, et al. Role of combined approach with radiotherapy and metallic stent in palliation of advanced cases of carcinoma esophagus - a pilot study. *JK Sci* 2002;4:130–5.
- Toucheffeu Y, Archambeaud I, Landi B, Lievre A, Lepere C, Rougier P, et al. Chemotherapy versus self-expanding metal stent as primary treatment of

- severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer. *Dig Liver Dis* 2014;46:283–6.
- [26] Techagumpuch A, Chanswangphuvana P, Pungpaong SU, Udomsawaengsup S, Navicharern P, Tharavej C. Compare result of definite chemoradiation combine with stent insertion and stent alone in advance esophageal carcinoma: a single institute, case series study, Thailand. *Gastrointest Endosc* 2014;79:AB416–7.
- [27] Toyokawa T, Horii J, Fujita I. Esophageal radiotherapy and metallic stenting are effective for the stenosis of advanced esophageal cancer; compared to stenting for patients without radiotherapy. *Gastrointest Endosc*. 2019;89:AB185.
- [28] Xie H, Zhang H, Wu K, Fan D. A comparison between radioactive and traditional stent in patients with advanced esophageal carcinoma. *J Gastroenterol Hepatol* 2013;28:673.
- [29] Park HS, Do YS, Suh SW, Choo SW, Lim HK, Kim SH, et al. Upper gastrointestinal tract malignant obstruction: Initial results of palliation with a flexible covered stent. *Radiology* 1999;210:865–70.
- [30] Balázs A, Kokas P, Lukovich P, Kupcsulik P. Palliative management of malignant oesophageal strictures with endoprosthesis implantation – 25 years experience. *Magyar sebészet* 2011;64:267–76.
- [31] Cwikiel M, Cwikiel W, Albertsson M. Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment. *Acta Oncol* 1996;35:75–9.
- [32] Rodrigues-Pinto E, Pereira P, Baron TH, Macedo G. Self-expandable metal stents are a valid option in patients with long-term survival from advanced esophageal cancer. *United Eur Gastroenterol J* 2017;5:A708.
- [33] Rueth NM, Shaw D, D’Cunha J, Cho C, Maddaus MA, Andrade RS. Esophageal stenting and radiotherapy: a multimodal approach for the palliation of symptomatic malignant dysphagia. *Ann Surg Oncol* 2012;19:4223–8.
- [34] Reed CE, Marsh WH, Carlson LS, Seymore CH, Kratz JM. Prospective, randomized trial of palliative treatment for unresectable cancer of the esophagus. *Ann Thorac Surg* 1991;51(4):552–6.
- [35] Han Y-T, Peng L, Fang Q, Li Q. Value of radiotherapy and chemotherapy after SEMS implantation operation in patients with malignant esophageal stricture. *Ai Zheng* 2004;23:682–4.
- [36] Zhang Y, Zhou M, Bai L, Han R, Lv K, Wang Z. Radiofrequency ablation combined with esophageal stent in the treatment of malignant esophageal stenosis: a single-center prospective study. *Oncol Lett* 2018;16:3157–61.
- [37] Homs MY, Steyerberg EW, Eijkenboom WM, Tilanus HW, Stalpers LJ, Bartelsman JF, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. *Lancet* 2004;364:1497–504.
- [38] Jiang XJ, Song MQ, Xin YN, Gao YQ, Niu ZY, Tian ZB. Endoscopic stenting and concurrent chemoradiotherapy for advanced esophageal cancer: A case-control study. *World J Gastroenterol* 2012;18:1404–9.
- [39] Leclaire S, Di Fiore F, Ben-Soussan E, Antonietti M, Hellot MF, Paillot B, et al. Prior chemoradiotherapy is associated with a higher life-threatening complication rate after palliative insertion of metal stents in patients with oesophageal cancer. *Aliment Pharmacol Ther* 2006;23:1693–702.
- [40] Guo JH, Teng GJ, Zhu GY, He SC, Fang W, Deng G, et al. Self-expandable esophageal stent loaded with I-125 seeds: initial experience in patients with advanced esophageal cancer. *Radiology* 2008;247:574–81.
- [41] Kim JY, Kim SG, Lim JH, Im JP, Kim JS, Jung HC. Clinical outcomes of esophageal stents in patients with malignant esophageal obstruction according to palliative additional treatment. *J Digest Dis* 2015;16:575–84.
- [42] Liu N, Liu SG, Xiang C, Cong N, Wang B, Zhou B, et al. Radioactive self-expandable stents give superior palliation in patients with unresectable cancer of the esophagus but should be used with caution if they have had prior radiotherapy. *Ann Thorac Surg* 2014;98:521–6.
- [43] Ludwig D, Dehne A, Burmester E, Wiedemann GJ, Stange EF. Treatment of unresectable carcinoma of the esophagus or the gastroesophageal junction by mesh stents with or without radiochemotherapy. *Int J Oncol* 1998;13:583–8.
- [44] Tian D, Wen H, Fu M. Comparative study of self-expanding metal stent and intraluminal radioactive stent for inoperable esophageal squamous cell carcinoma. *World J Surg Oncol* 2016;14:18.
- [45] Zhao P, Zhang M-Q, Zhang Y-L, Guo Y-C, Zhao Y-L, Wu Q-W, et al. Application of esophageal irradiation stents coated with 125I particles in advanced esophageal cancer. *J Buon* 2017;22(1):265–9.
- [46] Burstow M, Kelly T, Panchani S, Khan IM, Meek D, Memon B, et al. Outcome of palliative esophageal stenting for malignant dysphagia: a retrospective analysis. *Dis Esophagus* 2009;22:519–25.
- [47] Raijman I, Siddique I, Lynch P. Does chemoradiation therapy increase the incidence of complications with self-expanding coated stents in the management of malignant esophageal strictures?. *Am J Gastroenterol* 1997;92:2192–6.
- [48] Zhu HD, Guo JH, Mao AW, Lv WF, Ji JS, Wang WH, et al. Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable esophageal cancer: a multicentre, randomised phase 3 trial. *Lancet Oncol* 2014;15:612–9.
- [49] Javed A, Pal S, Dash NR, Ahuja V, Mohanti BK, Vishnubhatla S, et al. Palliative stenting with or without radiotherapy for inoperable esophageal carcinoma: a randomized trial. *J Gastrointest Cancer*. 2012;43:63–9.
- [50] Fu JH, Rong TH, Li XD, Yu H, Ma GW, Min HQ. Treatment of unresectable esophageal carcinoma by stenting with or without radiochemotherapy. *Zhonghua Zhong Liu Za Zhi* 2004;26:109–11.
- [51] Bakheet N, Hu HT, Park JH, Jeon JY, Yoon SH, Kim KY, et al. Clinical effectiveness and safety of self-expanding metal stent placement following palliative chemotherapy in patients with advanced esophageal cancer. *Abdom Radiol* 2020;45:563–70.
- [52] Xu XW, Di HT, Zhu J, Shi J. Complications related to conventional self-expandable metal stent insertion and internal irradiation stent insertion in patients with advanced esophageal carcinoma: An analysis of 32 cases. *J Interv Radiol* 2011;20:452–4.
- [53] Zhang S, Gao Y, Zhang J. Clinical research on treatment of esophageal carcinoma in advanced stage by metal stent in combination with radiotherapy. *Chin J Clin Oncol*, 2005;32(6):344-5+8.
- [54] Zhao P, Cui HK, Yang RM, Zhang XZ. The implantation of esophageal stent with radioactive 125I particles for advanced esophageal carcinomas: observation of therapeutic results. *J Interv Radiol* 2011;20:448–51.
- [55] Zhongmin W, Xunbo H, Jun C, Gang H, Kemin C, Yu L, et al. Intraluminal radioactive stent compared with covered stent alone for the treatment of malignant esophageal stricture. *Cardiovasc Intervent Radiol* 2012;35:351–8.
- [56] Zhong J, Wu Y, Xu Z, Liu X, Xu B, Zhai Z. Treatment of medium and late stage esophageal carcinoma with combined endoscopic metal stenting and radiotherapy. *Chin Med J (Engl)* 2003;116:24–8.
- [57] Dua KS. Stents for palliating malignant dysphagia and fistula: is the paradigm shifting?. *Gastrointest Endosc* 2007;65(1):77–81.
- [58] Homann N, Noftz MR, Klingenberg-Noftz RD, Ludwig D. Delayed complications after placement of self-expanding stents in malignant esophageal obstruction: treatment strategies and survival rate. *Dig Dis Sci* 2008;53:334–40.
- [59] Kozarek RA, Ball TJ, Brandabur JJ, Patterson DJ, Low D, Hill L, et al. Expandable versus conventional esophageal prostheses: easier insertion may not preclude subsequent stent-related problems. *Gastrointest Endosc* 1996;43:204–8.
- [60] Bown SG. Palliation of malignant dysphagia: surgery, radiotherapy, laser, intubation alone or in combination?. *Gut* 1991;32:841–4.
- [61] Song HY, Deok HL, Seo TS, Kim SB, Jung HY, Kim JH, et al. Retrievable covered nitinol stents: Experiences in 108 patients with malignant esophageal strictures. *J Vasc Interv Radiol* 2002;13:285–92.